Company Valuation: BioRestorative Therapies, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 15.16 10.1 8.19 9.895 10.43 5.215 - -
Change - -33.36% -18.94% 20.83% 5.4% -49.99% - -
Enterprise Value (EV) 15.16 10.1 8.19 9.895 10.43 5.215 5.215 5.215
Change - -33.36% -18.94% 20.83% 5.4% -49.99% 0% 0%
P/E -0.12x -0.54x -0.51x -1.23x -0.74x -0.41x -0.51x -0.5x
PBR - - - - - - - -
PEG - 0x 0x 0x -0x 0x 0x -0.41x
Capitalization / Revenue 330x 84.3x 56.2x 24.7x 29x 3.71x 2.26x 1.67x
EV / Revenue 0x 0x 0x 0x 0x 3.71x 2.26x 1.67x
EV / EBITDA - - - - - - - -
EV / EBIT -0x -0x -0x -0x -0x -0.38x -0.33x -0.29x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -37.3 -5.11 -3.42 -1.16 -1.58 -0.495 -0.405 -0.41
Distribution rate - - - - - - - -
Net sales 1 0.046 0.1198 0.1458 0.401 0.3597 1.405 2.312 3.125
EBITDA - - - - - - - -
EBIT 1 -26.31 -18.97 -15.22 -11.56 -15.65 -13.61 -15.67 -17.97
Net income 1 -44.3 -18.49 -14.42 -8.979 -14.24 -13.52 -15.56 -17.83
Net Debt - - - - - - - -
Reference price 2 4.3400 2.7500 1.7399 1.4300 1.1750 0.2047 0.2047 0.2047
Nbr of stocks (in thousands) 3,493 3,674 4,707 6,920 8,876 25,478 - -
Announcement Date 3/30/22 3/27/23 4/1/24 3/28/25 3/26/26 - - -
1USD in Million2USD
Estimates

P/E, Detailed evolution

P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
-0.41x - - - 5.22M
21.25x6.51x14.24x1.5% 56.54B
31.6x7.8x24.02x0.05% 53.6B
-17.91x4.18x-7.32x-.--% 22.91B
-38.6x12.23x-36.05x-.--% 21.37B
25.45x4.98x13.18x-.--% 20.27B
24.28x4.73x15.36x-.--% 17.56B
-737.38x35.03x-3943.97x-.--% 14.75B
40.7x16.37x42.16x0.09% 13.53B
16.68x4.82x11.24x-.--% 13.33B
Average -63.43x 10.74x -429.68x 0.18% 23.39B
Weighted average by Cap. -32.07x 9.11x -238.39x 0.38%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. BRTX Stock
  4. Valuation BioRestorative Therapies, Inc.